The biology underlying the approval is rooted in one of the most consequential discoveries in modern cancer genetics. DNA mismatch repair is a cellular quality-control system responsible for correcting errors that arise when DNA is copied during cell division. When the genes encoding this machinery, most commonly MLH1, MSH2, MSH6, or PMS2, are defective or silenced, errors accumulate in stretches of repetitive DNA known as microsatellites, producing a state called microsatellite instability. The resulting tumors carry an exceptionally high burden of mutations, and those mutations are translated into abnormal protein fragments that the immune system can recognize as foreign. This neoantigen-rich environment explains why dMMR tumors respond unusually well to immune checkpoint inhibitors, drugs that release the molecular brakes, such as the PD-L1/PD-1 axis targeted by atezolizumab, that cancers use to evade immune destruction. Paradoxically, however, dMMR tumors are less sensitive to fluoropyrimidine-based chemotherapy, the historical backbone of adjuvant treatment, leaving a critical therapeutic gap that the ATOMIC trial was designed to close.

Colorectal cancer remains the second leading cause of cancer-related death worldwide, and stage III disease, in which cancer has spread to nearby lymph nodes but not to distant organs, represents a pivotal and potentially curable stage. For decades, the standard adjuvant treatment for all patients with stage III colon cancer, regardless of molecular subtype, has been chemotherapy with a fluoropyrimidine combined with oxaliplatin, typically delivered as the FOLFOX regimen. Yet even with this treatment, a substantial proportion of patients experience recurrence, and the diminished sensitivity of dMMR tumors to fluoropyrimidines meant that this subgroup derived comparatively limited benefit from the existing standard. That unmet need provided a strong scientific rationale for a biomarker-driven approach, one that would match the distinctive immunogenicity of dMMR tumors with an agent capable of exploiting it, rather than treating all stage III colon cancers as a single, uniform disease.

The ATOMIC trial enrolled 712 participants between September 2017 and January 2023 across the United States and in Germany, a scale of accrual that investigators attribute to the infrastructure of the National Cancer Institute’s National Clinical Trials Network. Patients with stage III colon cancer and confirmed mismatch repair deficiency were randomized to receive either standard adjuvant chemotherapy alone or chemotherapy combined with atezolizumab. The trial was designed with disease-free survival as its primary endpoint, while overall survival and safety were designated as secondary endpoints, a structure that enabled a comprehensive assessment of both the efficacy and the tolerability of integrating immunotherapy into the adjuvant setting, where patients have already been rendered surgically disease-free and treatment is intended to prevent relapse rather than shrink measurable tumors.

The results, recently published in The New England Journal of Medicine, were striking. Adding atezolizumab to standard adjuvant chemotherapy reduced the risk of cancer recurrence or death by fifty percent, a magnitude of benefit rarely achieved in the adjuvant treatment of gastrointestinal malignancies. After three years of follow-up, 86.3 percent of patients who received the combination remained disease-free, compared with 76.2 percent of those who received chemotherapy alone. In practical terms, the immunotherapy combination translated into roughly one additional patient in ten remaining free of cancer three years after surgery, an absolute improvement with profound implications for a disease in which recurrence after stage III diagnosis frequently presages incurable metastatic spread. The ten-percentage-point separation between the curves, sustained over years, provided the evidentiary foundation on which the regulatory decision was built.

Leadership of the Alliance for Clinical Trials in Oncology framed the approval as both a clinical and an institutional milestone. Evanthia Galanis, MD, DSc, Group Chair of the Alliance, said that the approval of atezolizumab for patients with stage III dMMR colon cancer is a significant milestone for patients and for the organization, noting that the ATOMIC trial demonstrates the potential of introducing immunotherapy earlier in the course of cancer treatment, when the disease is still potentially curable, with the goal of preventing recurrence and increasing the number of patients who can be cured. She added that the trial also demonstrates the power of the National Cancer Institute’s National Clinical Trials Network to conduct large, definitive trials that answer important questions in cancer management and translate those findings into a new standard of care, and that the results show what is possible when investigators across the country come together around a common goal.

Frank A. Sinicrope, MD, the Alliance Study Chair for ATOMIC and a Professor of Oncology and Clinical Investigator of the Mayo Foundation at the Mayo Clinic Comprehensive Cancer Center, emphasized the clinical and scientific significance of the findings. He said the results provide compelling evidence that immunotherapy can play an important role in reducing the risk of recurrence and death after surgery for patients with stage III dMMR colon cancer, and that the FDA approval is an important step in bringing the benefits demonstrated in the trial into routine clinical practice. He also underscored a broader principle that is increasingly shaping oncology: the approval reinforces the importance of understanding the molecular characteristics of a patient’s tumor and using that information to guide treatment. He expressed gratitude to the patients and investigators who made the study possible and helped establish the new treatment regimen.

The trial’s execution reflected a public-private partnership model that has become central to modern cancer drug development. ATOMIC was sponsored by the National Cancer Institute, part of the National Institutes of Health, and led by the Alliance within the NCI-funded National Clinical Trials Network. Genentech provided support to the study through a Cooperative Research and Development Agreement with the NCI, an arrangement that allowed an academic-public consortium to evaluate a commercial immunotherapy agent in a biomarker-defined population while retaining the scientific independence and broad accrual capacity characteristic of network trials. The Alliance itself unites more than 26,000 cancer specialists at 112 main institutions and nearly 1,500 affiliates across the United States and Canada, and also serves as a leading research base for the NCI Community Oncology Research Program, enabling practice-changing trials to reach patients in both academic centers and community settings.

The broader implications extend well beyond a single drug approval. ATOMIC adds to a growing body of evidence that mismatch repair deficiency is one of the most predictive biomarkers in oncology, a molecular signature that reliably identifies patients likely to benefit from checkpoint blockade across disease stages and tumor types. By moving immunotherapy from the metastatic and locally advanced settings into the adjuvant treatment of early-stage colon cancer, the trial demonstrates that immune checkpoint inhibition can prevent recurrence, not merely control established disease, and that earlier intervention may increase the number of patients who are ultimately cured. The approval also validates the strategy of biomarker-driven trial design, in which a molecularly defined subgroup is studied prospectively rather than discovered retrospectively, and it reinforces the value of disease-free survival as an endpoint capable of supporting regulatory decisions when the biological link to overall survival is well established.

For patients, the practical consequence is a new standard of care: those diagnosed with stage III colon cancer will now undergo molecular testing for mismatch repair status as a routine part of treatment planning, and those whose tumors are dMMR will be eligible to receive atezolizumab alongside fluoropyrimidine and oxaliplatin chemotherapy after surgery. The full description of the clinical trial is available through ClinicalTrials.gov under identifier NCT02912559, and the primary results were published by Sinicrope and colleagues in The New England Journal of Medicine in March 2026. As immunotherapy continues its migration earlier into the treatment course of cancers with recognizable immune vulnerabilities, the ATOMIC trial and the approval it produced stand as a template for how large cooperative-group studies, molecular diagnostics, and public-private collaboration can converge to convert fundamental insights about tumor immunology into tangible gains in survival.

Subject of Research: Adjuvant immunotherapy with atezolizumab for stage III deficient DNA mismatch repair colon cancer based on the phase III ATOMIC trial

Article Title: Alliance announces FDA approval of atezolizumab based on results from the Phase III ATOMIC trial for patients with Stage III dMMR colon cancer

Article References: Alliance announces FDA approval of atezolizumab based on results from the Phase III ATOMIC trial for patients with Stage III dMMR colon cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: atezolizumab, colon cancer, dMMR, microsatellite instability, immunotherapy, ATOMIC trial, adjuvant chemotherapy, FDA approval, clinical trial, Alliance for Clinical Trials in Oncology, National Cancer Institute, disease-free survival